Dec 27, 2025 • MarketBeat
SOMEWHAT-BULLISH
Rice Hall James & Associates LLC Sells 54,869 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Rice Hall James & Associates LLC has reduced its stake in ACADIA Pharmaceuticals Inc. by selling 54,869 shares, now holding 614,937 shares valued at approximately $13.12 million. This sale represents an 8.2% decrease in their position. Insider transactions also show sales totaling over $1 million, though institutions largely maintain high ownership with a "Moderate Buy" consensus from analysts.
Dec 23, 2025 • Investing.com Nigeria
BULLISH
Acadia Pharmaceuticals stock reaches 52-week high at $27.73 By Investing.com
Acadia Pharmaceuticals stock aggressively rose to a 52-week high of $27.73, marking a 61% increase over the past year and reflecting strong investor confidence. The company's financial health is rated "GREAT" with a robust current ratio of 3.02, and it appears undervalued despite its strong performance. Recent FDA approval for DAYBUE STIX and varied analyst price target adjustments further contribute to its positive outlook.
Dec 22, 2025 • Investing.com
BULLISH
Acadia Pharmaceuticals stock reaches 52-week high at $27.73
Acadia Pharmaceuticals Inc. (ACAD) has achieved a 52-week high of $27.73, representing a 61% increase over the past year. This milestone is supported by the company's "GREAT" financial health score of 3.64 and a robust current ratio of 3.02, reflecting strong investor confidence and solid market performance. Recent developments include FDA approval for DAYBUE STIX and varied analyst price target adjustments, generally indicating a positive outlook.
Dec 22, 2025 • Investing.com Canada
BULLISH
Acadia Pharmaceuticals stock reaches 52-week high at $27.73 By Investing.com
Acadia Pharmaceuticals stock has reached a 52-week high of $27.73, reflecting a 61% increase over the past year and strong investor confidence. The company maintains a "GREAT" financial health score and its stock appears undervalued at its current price. Recent FDA approval for DAYBUE STIX and varied analyst price target adjustments further contribute to a positive outlook for the biopharmaceutical firm.
Dec 21, 2025 • Simply Wall Street
SOMEWHAT-BULLISH
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Its Strong 12-Month Share Price Rally
ACADIA Pharmaceuticals (ACAD) has seen significant growth in its share price over the past year, up 61%, and is currently trading just below consensus price targets. Despite this rally, a detailed long-term cash flow analysis suggests the stock might be modestly undervalued, with a narrative fair value of $29.32 against a current price of $27.16. The valuation hinges on assumptions of durable double-digit growth and steady margins, and investors should consider potential risks like NUPLAZID’s concentration risk or setbacks in late-stage trials.
Dec 18, 2025 • Business Wire
SOMEWHAT-BULLISH
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced it will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, in San Francisco. Catherine Owen Adams, CEO, will represent the company, and a live webcast will be available on acadia.com. The company also highlighted its commitment to neurological and rare disease communities, with FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome, and a robust pipeline.